Flucas Ventures — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders.
BiotechHealthtechMenlo Park, US
Joseph S. Zakrzewski(Co-Founder & Director)Eric Easom(Co-Founder, President & CEO)inGeorge H. Talbot(Co-Founder & Senior Clinical Advisor)Michael R.K. (Dickon) Alley(Co-Founder, SVP Research Fellow, Head of Biology)Sanjay Chanda(Chief Development Officer)inLucy O. Day(Chief Financial Officer)in
PartnerAshley Flucas· solo GP
Co-investorsAdjuvant CapitalBioRock VenturesHatteras Venture PartnersMountain Group CapitalRA CapitalBiotechnology Value Fund
Oort provided identity security and threat detection, now part of Cisco as Cisco Identity Intelligence, offering visibility into an organization's identity population and helping move toward passwordless authentication.
CybersecurityEnterprise SoftwareSaaSHarvard, US
Matthew Caulfield(Executive Officer, Director)Matt Caulfield(Founder)in
Co-investors.406 Ventures645 VenturesArgon VenturesCisco InvestmentsDreamit VenturesEnergy Impact Partners+10 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.












